Common use of Notices and Amendments Clause in Contracts

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.7. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. (a) In the case of Braeburn: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Xxxxx Fax: +0 000 000 0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, X0X 0X0 Xxxxxx Attention: Xxxxxxx Xxxxxxxx Fax: +0 000 000 0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such noticeinternationally recognized international courier, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand and shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.70. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. (a) In the case of BraeburnSynergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Synergy CHC Corp. c/o Jxxx Xxxx 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Xxxxx Fax: +0 000 000 0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxx (b) jxxx@xxxxxxxxxxxxx.xxx with a copy to: Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Xxxxx, Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Dxxxx Mannheim E-mail: dxxxxxxxx@xxxxxx.xxx In the case of KnightHand: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, X0X 0X0 Xxxxxx [____________] Attention: Xxxxxxx Xxxxxxxx Fax: +0 000 000 0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx With with a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx Kxxxx Hxxxxxxx Xxxxxx Branzberg LLP 1000 Xxxxxx Xxxxxx, Xxxxx 0000 XxXxxx Xxxxxxx Ave. Suite 2600 MontrealXxxxxxxxxxxx, Quebec H3A 3N9 Canada Xxxxxxxxxxxx 00000 X.X.X. Attention: Xxxxxx Wxxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934Xxxxxxxx, AS AMENDED. Fax: +0 000 000 0000 III E-mail: xxxxxx@xxxx.xxxWXxxxxxxx@xxxxx.xxx Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the Licensed Products and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Synergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx SYNERGY CHC CORP. 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel Jxxx Xxxx E-mail: jxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: Xxxxx Xxxxx W. Dxxxx Mannheim, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxdxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx KNIGHT THERAPEUTICS INC. 3000 xx Xxxxxxxxxxx Xxxx Xxxxx 000 0000 Xxxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0 Xxxxxx Attention: Xxxxxxx Xxxxxxxx Jxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000)000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxx-xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Synergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx SYNERGY CHC CORP. 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel Jxxx Xxxx E-mail: jxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LIP 4000 Xxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: Xxxxx Xxxxx W. Dxxxx Mannheim, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxdxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx KNIGHT THERAPEUTICS INC. 3000 xx Xxxxxxxxxxxx Xxxxx 000 0000 Xxxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0 Xxxxxx Attention: Xxxxxxx Xxxxxxxx Jxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxx-xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.7. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburn: Braeburn Pharmaceuticals, Inc. 00 40 Xxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx nxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Hxxxx Lovells US LLP 000 100 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Axxxx Xxxxx Fax: +0 000 000 0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxaxxxx.xxxxx@xxxxxxxxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 300 Xxxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, X0X 0X0 Xxxxxx Attention: Xxxxxxx Jxxxxxx Xxxxxxxx Fax: +0 000 000 0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec Québec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburn: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx the Sneaky Vaunt Corp SNEAKY VAUNT CORP c/o Synergy CHC Corp. 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel Jxxx Xxxx E-mail: jxxx@xxxxxxxxxx.xxx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: Xxxxx Xxxxx W. Dxxxx Mannheim, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxdxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 KNIGHT THERAPEUTICS (BARBADOS) INC. Txx Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxXxxxx, Xxxxxx, X0X 0X0 Xxxxxx Xx-Xxxxxxx XX00000 Barbados Attention: Xxxxxxx Mxxxxx Xxxxxxxx, President E-mail: mxxxxxxxx@xxxxxxxxx.xxx With a copy to: Davies Wxxx Xxxxxxxx & Vxxxxxxx LLP 900 Xxxxx Xxxxxx 00xx Xxxxx Xxx Xxxx, Xxx Xxxx 00000 U.S.A. Attention: Hxxxxx X. Xxxxx Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.7. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburn: Braeburn Pharmaceuticals, Inc. 00 40 Xxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Hxxxx Lovells US LLP 000 100 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Axxxx Xxxxx Fax: +0 000 000 0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxaxxxx.xxxxx@xxxxxxxxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 300 Xxxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, X0X 0X0 Xxxxxx Attention: Xxxxxxx Jxxxxxx Xxxxxxxx Fax: +0 000 000 0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec Québec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Nomad: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx NOMAD CHOICE PTY LTD. c/o Synergy Strips Corp. 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel Jxxx Xxxx E-mail: jxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: Xxxxx Xxxxx W. Dxxxx Mannheim, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxdxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 KNIGHT THERAPEUTICS INC. 300 Xxxxxxxx Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, Xxxxxx X0X 0X0 Xxxxxx Attention: Xxxxxxx Xxxxxxxx Jxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxx-xxxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Synergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx SYNERGY CHC CORP. 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel Xxxx Xxxx E-mail: xxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxxx Xxxxxxx Xxxxx Lovells US & Xxxxxx LLP 000 Xxxxxxxxxxxxx 0000 Xxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxx Xxxxxxxx, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxKNIGHT THERAPEUTICS INC. 3400 de Maisonneuve West Suite 1055 Westmount, Xxxxxx, X0X 0X0 Xxxxxx Quebec H3Z 3B8 Attention: Xxxxxxx Xxxxxxxx Xxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000)000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxx-xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Nomad: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx NOMAD CHOICE PTY LTD. do Synergy Strips Corp. 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Xxxxx Fax: +0 000 000 0000 Jxxx Xxxx E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxjxxx.xxxx@xxxxxxxxxx.xx with a copy to: Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Xxxxx, Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Dxxxx Mannheim, Esq. Fax: (000) 000.0000 E-mail: dxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 KNIGHT THERAPEUTICS (BARBADOS) INC. Txx Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxXxxxx, Xxxxxx, X0X 0X0 Xxxxxx Xx-Xxxxxxx XX00000 Barbados Attention: Xxxxxxx Mxxxxx Xxxxxxxx, President E-mail: mxxxxxxxx@xxx-xxxxxx.xxx With a copy to: Davies Wxxx Xxxxxxxx & Vxxxxxxx LLP 900 Xxxxx Xxxxxx - 20xx Xxxxx Xxx Xxxx, Xxx Xxxx 00000 X.X.X. Attention: Hxxxxx X. Xxxxx Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Synergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx SYNERGY CHC CORP. 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel Xxxx Xxxx E-mail: xxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxxx Xxxxxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx & Xxxxxx LIP 0000 Xxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxx Xxxxxxxx, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxKNIGHT THERAPEUTICS INC. 3400 de Mainsonneuve Suite 1055 Westmount, Xxxxxx, X0X 0X0 Xxxxxx Quebec H3Z 3B8 Attention: Xxxxxxx Xxxxxxxx Xxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxx-xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe SVC: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx SNEAKY VAUNT CORP. do Synergy CI-IC Corp 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel Xxxx Xxxx E-mail: xxxx@xxxxxxxxxx.xxx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxxx Xxxxxxx Xxxxx Lovells US & Xxxxxx LLP 000 Xxxxxxxxxxxxx 0000 Xxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxx Xxxxxxxx, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxKNIGHT THERAPEUTICS INC. 0000 Xx Xxxxxxxxxxx Xxxx. West Suite 1055 Montreal, Xxxxxx, X0X 0X0 Xxxxxx Quebec H3Z 3B8 Attention: Xxxxxxx Xxxxxxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxxxxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Nomad: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx NOMAD CHOICE PTY LTD. c/o Synergy Strips Corp. 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel Xxxx Xxxx E-mail: xxxx.xxxx@xxxxxxxxxx.xx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxxx Xxxxxxx Xxxxx Lovells US & Xxxxxx LLP 000 Xxxxxxxxxxxxx 0000 Xxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxx Xxxxxxxx, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. KNIGHT THERAPEUTICS INC. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxSuite 220 Westmount, Xxxxxx, X0X 0X0 Xxxxxx Quebec H3Z 1C3 Attention: Xxxxxxx Xxxxxxxx Xxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxx-xxxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.712.7. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of BraeburnSynergy: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Synergy Strips Corp. c/o Jxxx Xxxx 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Fax: E-mail: jxxx.xxxx@xxxxxxxxxx.xx with a copy to: Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Xxxxx, Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxW. Dxxxx Mannheim, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Xxxxx Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxx dmann hxxx@ wy ri ck. c ox Xxxxxx Therapeutics (bBarbados) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Cxxxxxxx Xxxxx Xxxx Xxxxxx Xxxxx 000 XxxxxxxxxXxxxxxxxxx, XxxxxxXx. Mxxxxxx BB11128 Barbados, X0X 0X0 Xxxxxx WI Attention: Xxxxxxx Axxxxx X. Xxxxxxxx Fax: +0 000 000 1-000-000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal900 Xxxxx Xxxxxx 00xx Xxxxx Xxx Xxxx, Quebec H3A 3N9 Canada XX 00000 LJ.S.A. Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 0000 E(000)000-mail: xxxxxx@xxxx.xxx0000

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburn: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx the Sneaky Vaunt Corp SNEAKY VAUNT CORP c/o Synergy CHC Corp. 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel Xxxx Xxxx E-mail: xxxx@xxxxxxxxxx.xxx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxxx Xxxxxxx Xxxxx Lovells US & Xxxxxx LLP 000 Xxxxxxxxxxxxx 0000 Xxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxx Xxxxxxxx, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxKNIGHT THERAPEUTICS (BARBADOS) INC. The Business Centre Upton, Xxxxxx, X0X 0X0 Xxxxxx St-Xxxxxxx BB11103 Barbados Attention: Xxxxxxx Xxxxxxxx Fax: +0 000 000 0000 Xxxxxx Xxxxxxxx, President E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxxxxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal000 Xxxxx Xxxxxx 00xx Xxxxx New York, Quebec H3A 3N9 Canada New York 10022 U.S.A. Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe SVC: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx SNEAKY VAUNT CORP. do Synergy CI-IC Corp 800 Xxxxxx Xxxxx 000 Xxxxxx Xxxxxxxxx, XX Xxxxx 00000 Xxxxxx Xxxxxx Attention: General Counsel Jxxx Xxxx E-mail: jxxx@xxxxxxxxxx.xxx with copies (which shall not constitute notice) a copy to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Wxxxxx Rxxxxxx Yxxxx & Pxxxxx LLP 4000 Xxxx Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 XxxxxxxxxXxxxx, XX 00000 Xxxxxx Xxxxxx Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: Xxxxx Xxxxx W. Dxxxx Mannheim, Esq. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxdxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx KNIGHT THERAPEUTICS INC. 3000 Xx Xxxxxxxxxxx Xxxx. Xxxx Xxxxx 0000 Xxxxxxxx, Xxxxxx Xxxxx 000 Xxxxxxxxx, Xxxxxx, X0X 0X0 Xxxxxx Attention: Xxxxxxx Xxxxxxxx Jxxxxxx Xxxxxxxx, Chief Financial Officer Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx jxxxxxxxx@xxxxxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Wxxx Xxxxxxxx & Xxxxxxxx Vxxxxxxx LLP 0000 1000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal, Quebec H3A 3N9 Canada Attention: Xxxxxx Hxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxxhxxxxx@xxxx.xxx

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.77.6. Notices and other communications shall be addressed as follows: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.: (a) In the case of Braeburnthe Nomad: Braeburn Pharmaceuticals, Inc. 00 Xxxxxxx Xxxxxx Xxxxx NOMAD CHOICE PTY LTD. do Synergy Strips Corp. 000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Westbrook, Maine 04092 Attention: General Counsel with copies (which shall not constitute notice) to: xxxxxxx@xxxxxxxxxxxxxx.xxx and Xxxxx Lovells US LLP 000 Xxxxxxxxxxxxx Xxxxx Xxxxx 0000 Xxxxxxxxx, XX 00000 Xxxxxx Xxxxxx Attention: Xxxxx Xxxxx Fax: +0 000 000 0000 Xxxx Xxxx E-mail: xxxxx.xxxxx@xxxxxxxxxxxx.xxxxxxx.xxxx@xxxxxxxxxx.xx with a copy to: Xxxxxx Xxxxxxx Xxxxx & Xxxxxx LLP 0000 Xxxx Xxxxx Xxxxx, Suite 300 Raleigh, North Carolina 27607 U.S.A. Attention: W. Xxxxx Xxxxxxxx, Esq. Fax: (000) 000.0000 E-mail: xxxxxxxxx@xxxxxx.xxx (b) In the case of Knight: Knight Therapeutics Inc. 000 Xxxxxxxx Xxxxxx Xxxxx 000 XxxxxxxxxKNIGHT THERAPEUTICS (BARBADOS) INC. The Business Centre Upton, Xxxxxx, X0X 0X0 Xxxxxx St-Xxxxxxx BB11103 Barbados Attention: Xxxxxxx Xxxxxxxx Fax: +0 000 000 0000 Xxxxxx Xxxxxxxx, President E-mail: xxxxxxxxx@xxx-Xxxxxx.xxx xxxxxxxxx@xxx-xxxxxx.xxx With a copy (which shall not constitute notice) to: Davies Xxxx Xxxxxxxx & Xxxxxxxx LLP 0000 XxXxxx Xxxxxxx Ave. Suite 2600 Montreal000 Xxxxx Xxxxxx - 00xx Xxxxx New York, Quebec H3A 3N9 Canada New York 10022 U.S.A. Attention: Xxxxxx X. Xxxxx CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Fax: +0 000 000 (000) 000-0000 E-mail: xxxxxx@xxxx.xxx